Total Payments
$291,571
2024 Payments
$82,830
Companies
29
Transactions
319
Medicare Patients
925
Medicare Billing
$157,422
Payment Breakdown by Category
Consulting$188,997 (64.8%)
Other$55,233 (18.9%)
Travel$22,955 (7.9%)
Research$12,884 (4.4%)
Food & Beverage$6,759 (2.3%)
Education$4,743 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $188,997 | 89 | 64.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,273 | 29 | 9.0% |
| Travel and Lodging | $22,955 | 51 | 7.9% |
| Grant | $18,182 | 1 | 6.2% |
| Unspecified | $12,884 | 24 | 4.4% |
| Honoraria | $10,778 | 2 | 3.7% |
| Food and Beverage | $6,759 | 109 | 2.3% |
| Education | $4,743 | 14 | 1.6% |
Payments by Type
General
$278,687
295 transactions
Research
$12,884
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $48,552 | 36 | $0 (2024) |
| EMD Serono, Inc. | $43,760 | 66 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $23,984 | 43 | $0 (2024) |
| Merck KGaA | $20,158 | 7 | $0 (2023) |
| Genentech, Inc. | $18,182 | 1 | $0 (2023) |
| Daiichi Sankyo Inc. | $15,121 | 19 | $0 (2024) |
| AstraZeneca UK Limited | $14,447 | 29 | $0 (2024) |
| Blueprint Medicines Corporation | $14,239 | 22 | $0 (2023) |
| ABBVIE INC. | $12,890 | 8 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,087 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $82,830 | 82 | AstraZeneca Pharmaceuticals LP ($18,135) |
| 2023 | $78,984 | 84 | Genentech, Inc. ($18,182) |
| 2022 | $47,663 | 49 | Merck KGaA ($16,308) |
| 2021 | $43,855 | 32 | AstraZeneca Pharmaceuticals LP ($14,728) |
| 2020 | $10,978 | 16 | EMD Serono, Inc. ($6,196) |
| 2019 | $15,662 | 26 | EMD Serono, Inc. ($13,344) |
| 2018 | $11,600 | 30 | AstraZeneca UK Limited ($4,500) |
All Payment Transactions
319 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| 12/24/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 12/19/2024 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $5,437.50 | General |
| 12/19/2024 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 12/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 12/12/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,260.00 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $88.10 | General |
| Category: Oncology | ||||||
| 12/11/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,712.50 | General |
| 12/07/2024 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $93.89 | General |
| 12/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $89.47 | General |
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 11/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $79.11 | General |
| Category: ONCOLOGY | ||||||
| 11/24/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $50.13 | General |
| Category: ONCOLOGY | ||||||
| 11/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $36.83 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $102.40 | General |
| Category: Oncology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.62 | General |
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $59.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 10/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MS200095-0031 | EMD Serono, Inc. | $6,302 | 1 |
| A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Regeneron Pharmaceuticals, Inc. | $1,869 | 8 |
| Tepotinib Lung Cancer Clinical Trial | EMD Serono, Inc. | $1,650 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH TABRECTA RESEARCH | Novartis Pharmaceuticals Corporation | $1,384 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $983.00 | 1 |
| A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study). | EMD Serono, Inc. | $696.10 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 219 | 389 | $155,600 | $36,840 |
| 2022 | 6 | 236 | 431 | $153,368 | $39,172 |
| 2021 | 8 | 266 | 482 | $208,629 | $52,771 |
| 2020 | 5 | 204 | 333 | $139,684 | $28,639 |
Total Patients
925
Total Services
1,635
Medicare Billing
$157,422
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 53 | 151 | $80,583 | $16,824 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 62 | 111 | $29,462 | $8,176 | 27.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 49 | 49 | $28,021 | $6,934 | 24.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 23 | 31 | $8,262 | $2,343 | 28.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 19 | 32 | $5,468 | $1,650 | 30.2% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2023 | 13 | 15 | $3,804 | $912.60 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 53 | 139 | $71,145 | $15,467 | 21.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 84 | 177 | $44,834 | $13,265 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 37 | 37 | $20,137 | $5,269 | 26.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 28 | 40 | $10,128 | $3,069 | 30.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 23 | 27 | $4,444 | $1,410 | 31.7% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2022 | 11 | 11 | $2,680 | $690.94 | 25.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 91 | 281 | $138,939 | $32,898 | 23.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 55 | 55 | $29,572 | $7,828 | 26.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 45 | 55 | $13,598 | $4,114 | 30.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $9,624 | $2,627 | 27.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 19 | $5,377 | $1,609 | 29.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 15 | 19 | $4,661 | $1,570 | 33.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 17 | 24 | $3,792 | $1,288 | 34.0% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Facility | 2021 | 13 | 13 | $3,066 | $837.07 | 27.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 95 | 200 | $95,607 | $17,326 | 18.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 44 | 44 | $24,576 | $5,990 | 24.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 34 | 51 | $11,964 | $3,243 | 27.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 15 | 20 | $4,741 | $1,312 | 27.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 16 | 18 | $2,796 | $767.34 | 27.4% |
About Dr. Xiuning Le, M.D
Dr. Xiuning Le, M.D is a Specialist healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2010. The National Provider Identifier (NPI) number assigned to this provider is 1720399074.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Xiuning Le, M.D has received a total of $291,571 in payments from pharmaceutical and medical device companies, with $82,830 received in 2024. These payments were reported across 319 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($188,997).
As a Medicare-enrolled provider, Le has provided services to 925 Medicare beneficiaries, totaling 1,635 services with total Medicare billing of $157,422. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Internal Medicine
- Location Boston, MA
- Active Since 07/01/2010
- Last Updated 09/02/2016
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1720399074
Products in Payments
- TAGRISSO (Drug) $22,103
- RYBREVANT (Drug) $19,848
- TEPMETKO (Drug) $16,308
- Tepotinib $11,802
- IMFINZI (Biological) $11,303
- LIBTAYO (Biological) $7,587
- TABRECTA (Drug) $6,267
- GILOTRIF (Drug) $5,494
- Enhertu (Drug) $4,946
- Tepmetko (Drug) $4,400
- ONIVYDE (Drug) $2,500
- Bavencio (Drug) $2,200
- Vitrakvi (Drug) $1,865
- ALIMTA (Drug) $700.00
- Tepotinib (Drug) $696.10
- EMD 1214063 (Biological) $635.69
- CYRAMZA (Drug) $130.50
- ZEPZELCA (Drug) $103.80
- IMFINZI (Drug) $100.14
- Alecensa (Biological) $72.05
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Boston
Keith Flaherty, Md, MD
Specialist — Payments: $1.4M
Specialist $1.4M
Dr. Caroline Baumal, Md, MD
Specialist — Payments: $988,075
Specialist $988,075
Dr. Paul Zei, M.d., Ph.d, M.D., PH.D
Specialist — Payments: $768,186
Specialist $768,186
Dr. Aman Patel, M.d, M.D
Specialist — Payments: $712,473
Specialist $712,473
Dr. Steven Treon, Md, Phd, MD, PHD
Specialist — Payments: $464,440
Specialist $464,440
Dr. Adam Rogers, M.d, M.D
Specialist — Payments: $316,568
Specialist $316,568